Home
  • Home
  • Resources
  • Diseases
  • Compendium
  • Training
  • Evaluation
    • The Tool
    • The Tutorial
  • SYSVAC
    • About
    • Registry
    • E-learning courses
  • News
  • Webinars
  • Network
    • Steering Committee
    • Vision and Mission
    • Map
    • Meetings
    • Partners
    • Join us
  • Home
  • Compendium
  • Hexavalent vaccines
Vaccine Evidence Compendium

Hexavalent vaccines

General indicators
    • Number of new cases per year (last 3-5 years)
    • Proportion of the population affected by the disease or infected with the antigen
    • Serogroup or serotype distribution (for serogroup- or serotype-specific vaccines)
    • Number of deaths from the disease per year
    • Case Fatality ratio (number of deaths / number of new cases, in %)
    • Outbreak, epidemic or pandemic risk
    • Contribution of the vaccine to achievement of the national, regional or global disease goals
    • Serogroup or serotype coverage by vaccines considered (for serogroup- or serotype-specific vaccines)
    • Efficacy and effectiveness estimates (e.g. against infection, disease, hospitalization, death), including in different populations
    • Duration of protection and waning of immunity in general and risk groups
    • Type, including severity, consequences and frequency of short- and long-term adverse events following vaccination
    • Perception of the target population on the risk of disease
    • Acceptability of the vaccine and of vaccination against the disease
    • Estimated financial cost of materials per vaccine dose (syringes, needles, safety box) (in USD)
    • Estimated vaccine financial cost per dose (in USD)
    • Estimated financial cost per person vaccinated (in USD)
    • Cost-effectiveness ratio
    • Is there a Gavi programme to support the introduction of this vaccine? If a Gavi programme is available, what support is available to countries?
    • Available vaccines, licensing status, prequalification status, presentation, formulation, dosage and route of administration
    • Number of doses and timing of administrations
    • Cold chain volume required per vaccine dose (in cm3)
Cold chain volume required per vaccine dose (in cm3)

For those vaccines that have vial presentation (3 out of 4) the cold-chain space requirements varies between 2.11 and 11.32 cm3/vial Go to footnote 11

Sources
  • Go back to footnote reference 11.

    Detailed information can be found in the vaccine comparison tables

  • Home
  • Resources
  • Diseases
  • Compendium
  • Training
  • Evaluation
  • SYSVAC
  • News
  • Webinars
  • Network
  • Sign in / Register
National Immunization Technical Advisory Groups
  • Home
  • Resources
  • Diseases
  • Compendium
  • Training
  • Evaluation
  • SYSVAC
  • News
  • Webinars
  • Network
© 2025
  • Legal Notice
Subscription to the monthly updates

At the end of each month, we share the latest NITAG recommendations from across all regions, highlight key articles related to NITAG activities, and provide important announcements. Stay informed - don’t miss out!

Loading...